Ottimo Pharma Ltd. is equipped to file an IND and take its lead bifunctional antibody into phase II development, after closing a $140 million series A. The round will accelerate development of ...

These people are prohibited from using well-known antipyretic drugs Roche submits clinical trial applications for TIGIT inhibitor and VEGF/Ang2 dual antibody in China ...

Source: Shutterstock Researchers compared the nephrotoxicity of VEGF tyrosine kinase inhibitor (TKI) therapy alone, the combination of a VEGF TKI and an immune checkpoint inhibitor (ICI), and ICI ...

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

As the MDGs era comes to a conclusion with the end of the year, 2016 ushers in the official launch of the bold and transformative 2030 Agenda for Sustainable Development adopted by world leaders ...

As the trend towards the international dispersion of certain value chain activities produces challenges, discover policies to meet these Tax transparency and international co-operation Enhanced ...

EMT is a form of cellular reprogramming that allows epithelial cells to acquire a mesenchymal phenotype, essential for embryonic development and adult tissue maintenance ... Key angiogenic regulators, ...

In this study, we aimed to compare the efficacy and safety of immune checkpoint inhibitors (ICIs) in patients with epidermal growth factor receptor (EGFR)-mutated NSCLC. Methods: The electronic ...

BioNTech obtained the candidate when it bought Biotheus last month in an acquisition deal that could reach up to $950 million. BioNTech on Tuesday revealed Phase Ib/II data for its investigational ...